Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

yttrium Y 90-DOTA-girentuximab

A radioimmunoconjugate comprised of girentuximab conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and lableled with the beta-emitting radioisotope yttrium Y 90. The antibody moiety of yttrium Y 90-DOTA-girentuximab binds to renal cell carcinoma cells expressing the G250 antigen, thereby selectively delivering a cytotoxic dose of beta radiation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:yttrium Y 90 DOTA chimeric monoclonal antibody cG250
Abbreviation:90Y-DOTA-cG250
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search